N/A
Completed N=54
Impact of Vitamin D on Diabetic Kidney Disease in African Americans
Source: ClinicalTrials.gov NCT01214356 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcomePrimary: Change in Urinary Albumin:Creatinine Ratio (ACR) — -52.55555556; 46.44444444 ratio
Summary
This purpose of this project is to evaluate the effectiveness of vitamin D supplementation over 12 months in vitamin D deficient African American adults with type 2 diabetes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Urinary Albumin:Creatinine Ratio (ACR) |
-52.55555556; 46.44444444 | — |
| SECONDARY Decrease in Estimated Glomerular Filtration Rate (eGFR) |
— | — |
Eligibility Criteria
Inclusion Criteria
- African American race
- Diagnosis of Type 2 Diabetes
- Stage 1 or 2 Kidney Disease with detectable microalbuminuria >4.0 (mg/g) 25(OH)D level Stage 3 Kidney Disease, or history of dialysis, kidney transplantation or nephrolithiasis
- Unable to provide informed consent or contact information
- Pre-existing calcium or parathyroid condition, including serum calcium >10.2 mg/dL
- Sarcoidosis, active tuberculosis, or malignancy
- Known hypersensitivity to vitamin D or any of its analogues and derivatives
- Current pregnancy or planning to become pregnant in next 15 months
Data sourced from ClinicalTrials.gov (NCT01214356). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.